Melatonin treatment following stroke induction modulates l-arginine metabolism

Journal of Pineal Research

Volumn 51, Issue 3, 2011, Pages 313-323

  Nair, Shiva M ^a   Rahman, Rosanna M A ^a   Clarkson, Andrew N ^a   Sutherland, Brad A ^a   Taurin, Sebastien ^a   Sammut, Ivan A ^a   Appleton, Ian ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

arginase; ischemic stroke; Melatonin; middle cerebral artery occlusion; nitric oxide synthase

Indexed keywords

ACONITATE HYDRATASE; ARGINASE; ARGINASE 1; ARGINASE II; ARGININE; CITRATE SYNTHASE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; MELATONIN; NEURONAL NITRIC OXIDE SYNTHASE; NITRITE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SUCCINATE DEHYDROGENASE (UBIQUINONE); UBIQUINOL CYTOCHROME C REDUCTASE; UNCLASSIFIED DRUG;

AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN CORTEX; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; EXPOSURE; FIBROBLAST; FIBROSARCOMA; HUMAN; HUMAN CELL; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; RAT; STROKE; TISSUE LEVEL;

ANIMALS; ARGININE; BLOTTING, WESTERN; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; MALE; MELATONIN; MIDDLE CEREBRAL ARTERY; NITRIC OXIDE SYNTHASE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RATS, SPRAGUE-DAWLEY; STROKE;

EID: 80053196136     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2011.00891.x     Document Type: Article

References (65)

1. Guilbert JJ,. The world health report 2002-reducing risks, promoting healthy life. Educ Health (Abingdon) 2003; 16: 230.
2. Lees KR, Bluhmki E, Von Kummer R, et al., Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695-1703.
3. Williams M, Patil S, Toledo EG, et al., Management of acute ischemic stroke: current status of pharmacological and mechanical endovascular methods. Neurol Res 2009; 31: 807-815.
4. Mergenthaler P, Dirnagl U, Meisel A,. Pathophysiology of stroke: lessons from animal models. Metab Brain Dis 2004; 19: 151-167. (Pubitemid 39361178)
5. White BC, Sullivan JM, DeGracia DJ, et al., Brain ischemia and reperfusion: molecular mechanisms of neuronal injury. J Neurol Sci 2000; 179: 1-33.
6. Haeberlein SL,. Mitochondrial function in apoptotic neuronal cell death. Neurochem Res 2004; 29: 521-530. (Pubitemid 38295003)
7. Szeto HH,. Mitochondria-targeted peptide antioxidants: novel neuroprotective agents. AAPS J 2006; 8: E521-E531.
8. Clarkson AN, Rahman R, Appleton I,. Inflammation and autoimmunity as a central theme in neurodegenerative disorders: fact or fiction? Curr Opin Investig Drugs 2004; 5: 706-713.
9. Appleton I, Tomlinson A, Willoughby DA,. Induction of cyclo-oxygenase and nitric oxide synthase in inflammation. Adv Pharmacol 1996; 35: 27-78.
10. Gartner MH, Shearer JD, Bereiter DF, et al., Wound fluid amino acid concentrations regulate the effect of epidermal growth factor on fibroblast replication. Surgery 1991; 110: 448-455; discussion 455-446.
11. McCullough L, Wu L, Haughey N, et al., Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci 2004; 24: 257-268. (Pubitemid 38181690)
12. Kawano T, Anrather J, Zhou P, et al., Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med 2006; 12: 225-229. (Pubitemid 43214750)
13. Moro MA, Cardenas A, Hurtado O, et al., Role of nitric oxide after brain ischaemia. Cell Calcium 2004; 36: 265-275. (Pubitemid 38992352)
14. Clarkson AN, Liu H, Pearson L, et al., Neuroprotective effects of spermine following hypoxic-ischemic-induced brain damage: a mechanistic study. FASEB J 2004; 18: 1114-1116. (Pubitemid 39561541)
15. Reiter RJ, Tan DX, Maldonado MD,. Melatonin as an antioxidant: physiology versus pharmacology. J Pineal Res 2005; 39: 215-216. (Pubitemid 41140762)
16. Hardeland R, Tan DX, Reiter RJ,. Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J Pineal Res 2009; 47: 109-126.
17. Reiter RJ, Tan DX, Leon J, et al., When melatonin gets on your nerves: its beneficial actions in experimental models of stroke. Exp Biol Med (Maywood) 2005; 230: 104-117.
18. Korkmaz A, Reiter RJ, Topal T, et al., Melatonin: an established antioxidant worthy of use in clinical trials. Mol Med 2009; 15: 43-50.
19. Macleod MR, O'Collins T, Horky LL, et al., Systematic review and meta-analysis of the efficacy of melatonin in experimental stroke. J Pineal Res 2005; 38: 35-41. (Pubitemid 40139308)
20. Cervantes M, Morali G, Letechipia-Vallejo G,. Melatonin and ischemia-reperfusion injury of the brain. J Pineal Res 2008; 45: 1-7. (Pubitemid 351986258)
21. Samantaray S, Das A, Thakore NP, et al., Therapeutic potential of melatonin in traumatic central nervous system injury. J Pineal Res 2009; 47: 134-142.
22. Tocharus J, Khonthun C, Chongthammakun S, et al., Melatonin attenuates methamphetamine-induced overexpression of pro-inflammatory cytokines in microglial cell lines. J Pineal Res 2010; 48: 347-352.
23. Tan DX, Chen LD, Poeggeler B, et al., Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr J 1993; 1: 57-60.
24. Koh PO,. Melatonin regulates nitric oxide synthase expression in ischemic brain injury. J Vet Med Sci 2008; 70: 747-750.
25. Pohjanpelto P, Holtta E,. Arginase activity of different cells in tissue culture. Biochim Biophys Acta 1983; 757: 191-195. (Pubitemid 13104002)
26. Longa EZ, Weinstein PR, Carlson S, et al., Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989; 20: 84-91. (Pubitemid 19040218)
27. Rahman RM, Nair SM, Helps SC, et al., (-)-Epigallocatechin gallate as an intervention for the acute treatment of cerebral ischemia. Neurosci Lett 2005; 382: 227-230. (Pubitemid 40733627)
28. Sutherland BA, Shaw OM, Clarkson AN, et al., Neuroprotective effects of (-)-epigallocatechin gallate following hypoxia-ischemia-induced brain damage: novel mechanisms of action. FASEB J 2005; 19: 258-260. (Pubitemid 40189274)
29. Bradford MM,. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
30. Pugazhenthi K, Kapoor M, Clarkson AN, et al., Melatonin accelerates the process of wound repair in full-thickness incisional wounds. J Pineal Res 2008; 44: 387-396. (Pubitemid 351533523)
31. R D evelopment C ore T eam. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria, 2010.
32. Guerrero JM, Reiter RJ, Ortiz GG, et al., Melatonin prevents increases in neural nitric oxide and cyclic GMP production after transient brain ischemia and reperfusion in the Mongolian gerbil (Meriones unguiculatus). J Pineal Res 1997; 23: 24-31. (Pubitemid 127500266)
33. Pei Z, Fung PC, Cheung RT,. Melatonin reduces nitric oxide level during ischemia but not blood-brain barrier breakdown during reperfusion in a rat middle cerebral artery occlusion stroke model. J Pineal Res 2003; 34: 110-118. (Pubitemid 36255919)
34. Pei Z, Cheung RT,. Pretreatment with melatonin exerts anti-inflammatory effects against ischemia/reperfusion injury in a rat middle cerebral artery occlusion stroke model. J Pineal Res 2004; 37: 85-91. (Pubitemid 39120211)
35. Alonso M, Collado PS, Gonzalez-Gallego J,. Melatonin inhibits the expression of the inducible isoform of nitric oxide synthase and nuclear factor kappa B activation in rat skeletal muscle. J Pineal Res 2006; 41: 8-14. (Pubitemid 43980689)
36. Gilad E, Wong HR, Zingarelli B, et al., Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibition of NFkappaB activation. FASEB J 1998; 12: 685-693. (Pubitemid 28247147)
37. Mazzon E, Esposito E, Crisafulli C, et al., Melatonin modulates signal transduction pathways and apoptosis in experimental colitis. J Pineal Res 2006; 41: 363-373. (Pubitemid 44498223)
38. Mohan N, Sadeghi K, Reiter RJ, et al., The neurohormone melatonin inhibits cytokine, mitogen and ionizing radiation induced NF-kappa B. Biochem Mol Biol Int 1995; 37: 1063-1070. (Pubitemid 26181750)
39. Gitto E, Romeo C, Reiter RJ, et al., Melatonin reduces oxidative stress in surgical neonates. J Pediatr Surg 2004; 39: 184-189; discussion 184-189. (Pubitemid 38146434)
40. Mollace V, Muscoli C, Masini E, et al., Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol Rev 2005; 57: 217-252. (Pubitemid 41043885)
41. Christianson DW,. Arginase: structure, mechanism, and physiological role in male and female sexual arousal. Acc Chem Res 2005; 38: 191-201. (Pubitemid 40388098)
42. Maarsingh H, Tio MA, Zaagsma J, et al., Arginase attenuates inhibitory nonadrenergic noncholinergic nerve-induced nitric oxide generation and airway smooth muscle relaxation. Respir Res 2005; 6: 23.
43. Li H, Meininger CJ, Hawker JR Jr, et al., Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. Am J Physiol Endocrinol Metab 2001; 280: E75-E82.
44. Buga GM, Singh R, Pervin S, et al., Arginase activity in endothelial cells: inhibition by NG-hydroxy-L-arginine during high-output NO production. Am J Physiol 1996; 271: H1988-H1998.
45. Zhang C, Hein TW, Wang W, et al., Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide-mediated vasodilatory function. FASEB J 2001; 15: 1264-1266.
46. Aladag MA, Turkoz Y, Parlakpinar H, et al., Melatonin ameliorates cerebral vasospasm after experimental subarachnoidal haemorrhage correcting imbalance of nitric oxide levels in rats. Neurochem Res 2009; 34: 1935-1944.
47. Landino LM, Crews BC, Timmons MD, et al., Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis. Proc Natl Acad Sci U S A 1996; 93: 15069-15074. (Pubitemid 27009553)
48. Iadecola C, Gorelick PB,. The Janus face of cyclooxygenase-2 in ischemic stroke: shifting toward downstream targets. Stroke 2005; 36: 182-185. (Pubitemid 40170777)
49. Cuzzocrea S, Costantino G, Mazzon E, et al., Regulation of prostaglandin production in carrageenan-induced pleurisy by melatonin. J Pineal Res 1999; 27: 9-14. (Pubitemid 29359453)
50. Dong WG, Mei Q, Yu JP, et al., Effects of melatonin on the expression of iNOS and COX-2 in rat models of colitis. World J Gastroenterol 2003; 9: 1307-1311. (Pubitemid 36805674)
51. Wu KK,. Control of cyclooxygenase-2 transcriptional activation by pro-inflammatory mediators. Prostaglandins Leukot Essent Fatty Acids 2005; 72: 89-93. (Pubitemid 40051225)
52. Deng WG, Tang ST, Tseng HP, et al., Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding. Blood 2006; 108: 518-524.
53. Negi G, Kumar A, Sharma SS,. Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-kappaB and Nrf2 cascades. J Pineal Res 2011; 50: 124-131.
54. De La Rocha N, Rotelli A, Aguilar CF, et al., Structural basis of the anti-inflammatory activity of melatonin. Arzneimittelforschung 2007; 57: 782-786.
55. Clarkson AN, Clarkson J, Jackson DM, et al., Mitochondrial involvement in transhemispheric diaschisis following hypoxia-ischemia: clomethiazole-mediated amelioration. Neuroscience 2007; 144: 547-561. (Pubitemid 44855307)
56. Martin M, Macias M, Escames G, et al., Melatonin-induced increased activity of the respiratory chain complexes I and IV can prevent mitochondrial damage induced by ruthenium red in vivo. J Pineal Res 2000; 28: 242-248. (Pubitemid 30255377)
57. Martin M, Macias M, Leon J, et al., Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria. Int J Biochem Cell Biol 2002; 34: 348-357. (Pubitemid 34164278)
58. Okatani Y, Wakatsuki A, Reiter RJ, et al., Protective effect of melatonin against mitochondrial injury induced by ischemia and reperfusion of rat liver. Eur J Pharmacol 2003; 469: 145-152. (Pubitemid 36629560)
59. Petrosillo G, Di Venosa N, Pistolese M, et al., Protective effect of melatonin against mitochondrial dysfunction associated with cardiac ischemia-reperfusion: role of cardiolipin. FASEB J 2006; 20: 269-276. (Pubitemid 44933174)
60. Wakatsuki A, Okatani Y, Shinohara K, et al., Melatonin protects against ischemia/reperfusion-induced oxidative damage to mitochondria in fetal rat brain. J Pineal Res 2001; 31: 167-172. (Pubitemid 32778166)
61. Petrosillo G, Colantuono G, Moro N, et al., Melatonin protects against heart ischemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening. Am J Physiol Heart Circ Physiol 2009; 297: H1487-H1493.
62. Wang X, Figueroa BE, Stavrovskaya IG, et al., Methazolamide and melatonin inhibit mitochondrial cytochrome C release and are neuroprotective in experimental models of ischemic injury. Stroke 2009; 40: 1877-1885.
63. Wang WZ, Fang XH, Stephenson LL, et al., Melatonin attenuates I/R-induced mitochondrial dysfunction in skeletal muscle. J Surg Res 2010; doi:.
64. Paradies G, Petrosillo G, Paradies V, et al., Melatonin, cardiolipin and mitochondrial bioenergetics in health and disease. J Pineal Res 2010; 48: 297-310.
65. Acuna-Castroviejo D, Escames G, Rodriguez MI, et al., Melatonin role in the mitochondrial function. Front Biosci 2007; 12: 947-963. (Pubitemid 46846869)